Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls… Read more
Hemagen Diagnostics Inc (HMGN) - Net Assets
Latest net assets as of September 2012: $-3.56 Million USD
Based on the latest financial reports, Hemagen Diagnostics Inc (HMGN) has net assets worth $-3.56 Million USD as of September 2012.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.44 Million) and total liabilities ($6.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.56 Million |
| % of Total Assets | -145.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -285.06% |
| Growth Volatility | 182.35 |
Hemagen Diagnostics Inc - Net Assets Trend (1993–2012)
This chart illustrates how Hemagen Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hemagen Diagnostics Inc (1993–2012)
The table below shows the annual net assets of Hemagen Diagnostics Inc from 1993 to 2012.
| Year | Net Assets | Change |
|---|---|---|
| 2012-09-30 | $-3.56 Million | -32.37% |
| 2011-09-30 | $-2.69 Million | -45.49% |
| 2010-09-30 | $-1.85 Million | -3.68% |
| 2009-09-30 | $-1.78 Million | -62.69% |
| 2008-09-30 | $-1.09 Million | +26.80% |
| 2007-09-30 | $-1.50 Million | -111.33% |
| 2006-09-30 | $-707.79K | +30.49% |
| 2005-09-30 | $-1.02 Million | -488.72% |
| 2004-09-30 | $261.96K | -86.37% |
| 2003-09-30 | $1.92 Million | -40.04% |
| 2002-09-30 | $3.21 Million | -32.77% |
| 2001-09-30 | $4.77 Million | -14.60% |
| 2000-09-30 | $5.58 Million | +13.94% |
| 1999-09-30 | $4.90 Million | -51.49% |
| 1998-09-30 | $10.10 Million | +1.00% |
| 1997-09-30 | $10.00 Million | +6.38% |
| 1996-09-30 | $9.40 Million | +394.74% |
| 1995-09-30 | $1.90 Million | -29.63% |
| 1994-09-30 | $2.70 Million | -28.95% |
| 1993-09-30 | $3.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hemagen Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2547823100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2012)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $156.00K | % |
| Other Comprehensive Income | $-78.55K | % |
| Other Components | $23.04 Million | % |
| Total Equity | $-3.56 Million | 100.00% |
Hemagen Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Hemagen Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Halitron Inc
PINK:HAON
|
$1.00 |
|
Hawk Systems Inc
PINK:HWSY
|
$1.00 |
|
China Electronics Holdings Inc
PINK:MSBN
|
$1.00 |
|
Zulu-Tek Inc
PINK:ZULU
|
$1.00 |
|
Roboserver Systems Corp
PINK:RBSY
|
$1.00 |
|
Associates First Capital Corp
PINK:ASFZ
|
$1.00 |
|
Crumbs Bake Shop Inc
PINK:CRMBQ
|
$1.00 |
|
Bourque Indts Inc
PINK:BORK
|
$1.00 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hemagen Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2011 to 2012, total equity changed from -2,687,070 to -3,556,801, a change of -869,731.
- Net loss of 907,315 reduced equity.
- Other comprehensive income decreased equity by 57,960.
- Other factors increased equity by 95,544.
Equity Change Factors (2011 to 2012)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-907.32K | -25.51% |
| Other Comprehensive Income | $-57.96K | -1.63% |
| Other Changes | $95.54K | +2.69% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hemagen Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-09-30 | $1.34 | $0.00 | x |
| 1994-09-30 | $0.86 | $0.00 | x |
| 1995-09-30 | $0.59 | $0.00 | x |
| 1996-09-30 | $1.50 | $0.00 | x |
| 1997-09-30 | $1.30 | $0.00 | x |
| 1998-09-30 | $1.26 | $0.00 | x |
| 1999-09-30 | $0.62 | $0.00 | x |
| 2000-09-30 | $0.58 | $0.00 | x |
| 2001-09-30 | $0.49 | $0.00 | x |
| 2002-09-30 | $0.32 | $0.00 | x |
| 2003-09-30 | $0.19 | $0.00 | x |
| 2004-09-30 | $0.03 | $0.00 | x |
| 2005-09-30 | $-0.07 | $0.00 | x |
| 2006-09-30 | $-0.05 | $0.00 | x |
| 2007-09-30 | $-0.10 | $0.00 | x |
| 2008-09-30 | $-0.07 | $0.00 | x |
| 2009-09-30 | $-0.12 | $0.00 | x |
| 2010-09-30 | $-0.12 | $0.00 | x |
| 2011-09-30 | $-0.17 | $0.00 | x |
| 2012-09-30 | $-0.23 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hemagen Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.45%
- • Asset Turnover: 1.65x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-98.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | -34.21% | -72.22% | 0.37x | 1.29x | $-1.68 Million |
| 1994 | -40.74% | -45.83% | 0.49x | 1.81x | $-1.37 Million |
| 1995 | -52.63% | -25.00% | 0.55x | 3.84x | $-1.19 Million |
| 1996 | -5.32% | -4.95% | 0.86x | 1.26x | $-1.44 Million |
| 1997 | 4.00% | 3.08% | 1.13x | 1.15x | $-600.00K |
| 1999 | -106.12% | -35.62% | 1.20x | 2.49x | $-5.69 Million |
| 2000 | -91.89% | -46.66% | 1.01x | 1.96x | $-5.69 Million |
| 2001 | -46.12% | -20.04% | 1.31x | 1.76x | $-2.68 Million |
| 2002 | -54.92% | -18.53% | 1.35x | 2.19x | $-2.08 Million |
| 2003 | -65.83% | -14.93% | 1.31x | 3.37x | $-1.46 Million |
| 2004 | -1373.93% | -48.18% | 1.33x | 21.47x | $-3.63 Million |
| 2005 | 0.00% | -17.63% | 1.42x | 0.00x | $-1.24 Million |
| 2006 | 0.00% | 6.55% | 1.09x | 0.00x | $383.70K |
| 2007 | 0.00% | -18.94% | 1.09x | 0.00x | $-700.35K |
| 2008 | 0.00% | 6.70% | 1.34x | 0.00x | $536.66K |
| 2009 | 0.00% | -14.91% | 1.46x | 0.00x | $-630.01K |
| 2010 | 0.00% | -2.99% | 1.55x | 0.00x | $28.38K |
| 2011 | 0.00% | -17.13% | 1.78x | 0.00x | $-611.77K |
| 2012 | 0.00% | -22.45% | 1.65x | 0.00x | $-551.63K |
Industry Comparison
This section compares Hemagen Diagnostics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hemagen Diagnostics Inc (HMGN) | $-3.56 Million | -34.21% | N/A | $1.00 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |